The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

被引：0
|
作者：
Gonchigdash, Chinbat [1 ]
Purevsuren, Baljinnyam [1 ]
Tungalag, Saruul [1 ]
Tungalagchimeg, Erdenechimeg [1 ]
Norov, Oyundelger [1 ]
机构：
[1] First Cent Hosp Mongolia, Ulaanbaatar, Mongolia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MPN; ruxolitinib; polycythemia vera; hydroxyurea;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-374
引用
收藏
页码：S430 / S430
页数：1
相关论文
共 34 条
  • [1] Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy
    Verstovsek, Srdan
    Harrison, Claire N.
    Kiladjian, Jean-Jacques
    Miller, Carole
    Naim, Ahmad B.
    Paranagama, Dilan C.
    Habr, Dany
    Vannucchi, Alessandro M.
    LEUKEMIA RESEARCH, 2017, 56 : 52 - 59
  • [2] THERAPY OF THE POLYCYTHEMIA VERA WITH RUXOLITINIB
    Melikyan, A. L.
    Subortseva, I. N.
    Gilyazitdinova, E. A.
    Kovrigina, A. M.
    Sudarikov, A. B.
    Abdullaev, A. O.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (04): : 229 - 232
  • [3] Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta-analysis
    Mora, M. Meritxell Roca
    Afzal, Farhan
    Guimaraes, Catharina Ribeiro
    Cunha, Luisa Marin
    Godoi, Amanda
    Marcolin, Patricia
    Valenzuela, S. Andres
    APMIS, 2024, 132 (11) : 775 - 786
  • [4] Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    Vannucchi, Alessandro M.
    Kiladjian, Jean Jacques
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Mesa, Ruben
    He, Shui
    Jones, Mark M.
    Garrett, William
    Li, Jingjin
    Pirron, Ulrich
    Habr, Dany
    Verstovsek, Srdan
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (05) : 426 - 435
  • [5] Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
    Verstovsek, Srdan
    Vannucchi, Alessandro M.
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Kirito, Keita
    Besses, Carlos
    Hino, Masayuki
    Moiraghi, Beatriz
    Miller, Carole B.
    Cazzola, Mario
    Rosti, Vittorio
    Blau, Igor
    Mesa, Ruben
    Jones, Mark M.
    Zhen, Huiling
    Li, Jingjin
    Francillard, Nathalie
    Habr, Dany
    Kiladjian, Jean-Jacques
    HAEMATOLOGICA, 2016, 101 (07) : 821 - 829
  • [6] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa Kathrin
    Gisslinger, Heinz
    Waltzman, Roger
    Stalbovskaya, Viktoriya
    McQuitty, Mari
    Hunter, Deborah S.
    Levy, Richard
    Knoops, Laurent
    Cervantes, Francisco
    Vannucchi, Alessandro M.
    Barbui, Tiziano
    Barosi, Giovanni
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) : 787 - 798
  • [7] Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
    Alvarez-Larran, Alberto
    Garrote, Marta
    Ferrer-Marin, Francisca
    Perez-Encinas, Manuel
    Mata-Vazquez, M. Isabel
    Bellosillo, Beatriz
    Arellano-Rodrigo, Eduardo
    Gomez, Montse
    Garcia, Regina
    Garcia-Gutierrez, Valentin
    Gasior, Mercedes
    Cuevas, Beatriz
    Angona, Anna
    Gomez-Casares, Maria Teresa
    Martinez, Clara M.
    Magro, Elena
    Ayala, Rosa
    del Orbe-Barreto, Rafael
    Perez-Lopez, Raul
    Fox, Maria Laura
    Raya, Jose-Maria
    Guerrero, Lucia
    Garcia-Hernandez, Carmen
    Caballero, Gonzalo
    Murillo, Ilda
    Xicoy, Blanca
    Ramirez, M. Jose
    Carreno-Tarragona, Gonzalo
    Hernandez-Boluda, Juan Carlos
    Pereira, Arturo
    CANCER, 2022, 128 (13) : 2441 - 2448
  • [8] Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Kvasnicka, Hans Michael
    Thiele, Juergen
    Bueso-Ramos, Carlos E.
    Sun, William
    Cortes, Jorge
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [9] Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis
    Mikkelsen, Stine Ulrik
    Kjaer, Lasse
    Bjorn, Mads Emil
    Knudsen, Trine Alma
    Sorensen, Anders Lindholm
    Andersen, Christen Bertel Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Pallisgaard, Niels
    Thomassen, Mads
    Skov, Vibe
    Hasselbalch, Hans Carl
    CANCER MEDICINE, 2018, 7 (08): : 3571 - 3581
  • [10] Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
    Harrison, Claire N.
    Mead, Adam J.
    Panchal, Anesh
    Fox, Sonia
    Yap, Christina
    Gbandi, Emmanouela
    Houlton, Aimee
    Alimam, Samah
    Ewing, Joanne
    Wood, Marion
    Chen, Frederick
    Coppell, Jason
    Panoskaltsis, Nicki
    Knapper, Steven
    Ali, Sahra
    Hamblin, Angela
    Scherber, Robyn
    Dueck, Amylou C.
    Cross, Nicholas C. P.
    Mesa, Ruben
    McMullin, Mary Frances
    BLOOD, 2017, 130 (17) : 1889 - 1897
1234